Is Cosentyx (secukinumab) approved for Crohn’s disease?
Cosentyx (secukinumab) is an IL-17A inhibitor. The provided information here does not include approval details for Crohn’s disease specifically, so I can’t confirm its current labeled indication from the available source set.
If you mean “can Cosentyx treat Crohn’s?”, what’s the usual clinical rationale?
Crohn’s disease is an inflammatory bowel disease, but the key biologic targets used in Crohn’s differ across drug classes (for example, TNF inhibitors, integrin blockers, and IL-12/23 or IL-23 pathway agents). Because Cosentyx targets IL-17A, it is not the typical first-line biologic class for Crohn’s treatment compared with other established pathways.
Are there alternatives for Crohn’s if Cosentyx isn’t the right fit?
Common biologic approaches for Crohn’s (depending on severity, prior therapies, and biomarker factors) usually involve:
- TNF inhibitors
- Integrin (adhesion) inhibitors
- IL-12/23 or IL-23 pathway inhibitors
- JAK inhibitors in certain situations
The right choice depends on prior response, steroid dependence, fistulizing disease, and safety considerations.
What to check next (so you get an accurate answer fast)
If you share any of the following, I can tailor the answer to the exact Crohn’s situation you’re asking about:
- Your country (approval labels can differ)
- Whether you mean “approved for Crohn’s” or “used off-label”
- Disease type (non-stricturing/non-penetrating vs stricturing vs fistulizing)
- Prior meds tried (anti-TNF, vedolizumab, ustekinumab, etc.)
Source
No reliable Cosentyx Crohn’s approval details were included in the information provided, and I don’t have an authorized source link to cite for this specific question.